ASTRAZENECA WKN: 886455 ISIN: GB0009895292 Kürzel: AZN Forum: Aktien Thema: Hauptdiskussion

3 June 2021 22:00 BST First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting Results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. The results will be presented during the plenary session of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on 6 June 2021 (abstract LBA#1) and were published today in The New England Journal of Medicine. An estimated 2.3 million people were diagnosed with breast cancer worldwide in 2020 and BRCA mutations are found in approximately 5% of breast cancer patients.1,2

Lynparza reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial

Anifrolumab showed benefit across different measures of skin and joint disease activity in patients with systemic lupus erythematosus

Wow

0,6%

AstraZeneca-Aktie steigt: AstraZeneca-Lungenkrebsmittel erhält EU-Zulassung 28.05.2021 10:01:00 Die AstraZeneca plc hat die Zulassung für ihr Medikament Tagrisso in der Europäischen Union zur Behandlung von Lungenkrebs im Frühstadium erhalten. Werbung  OSKAR, der ausgezeichnete ETF-Sparplan - jetzt downloaden Das Pharmaunternehmen teilte mit, dass die Ergebnisse der Phase-3-Studie Adaura zeigten, dass Tagrisso das Risiko eines Wiederauftretens der Krankheit oder des Todes um 80 Prozent reduziert. Werbung Tagrisso ist inzwischen in mehr als 50 Ländern zugelassen, darunter auch in den USA und China, so AstraZeneca.

https://orf.at/stories/3214872/

https://youtu.be/2feMR-jHW04

Moderna bin ich mal dabei steigt im Moment 👍Zieht bestimmt mit Biontech mit....

Einfach nachher mit Orgon-Energie bestrahlen lassen und genug belebtes Wasser trinken.

Was meinst du wie man seit Dekaden schon alle möglichen Vakzine herstellt?

Scheint ein geiles Zeugs zu sein, was da alles drin ist: Eine Dosis (0,5 ml) enthält: Schimpansen-Adenovirus, der das SARS-CoV-2-Spike-Glykoprotein (ChAdOx1-S)* kodiert, nicht weniger als 2,5 x 108 infektiöse Einheiten (IE) *Hergestellt in genetisch veränderten, humanen embryonalen Nieren 293-Zellen (HEK, human embryonic kidney) und durch rekombinante DNA-Technologie. Dieses Produkt enthält genetisch veränderte Organismen (GVOs). Nachzulesen bei: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_de.pdf

The government has arranged to buy 120 million doses of Astra's vaccine, enough to vaccinate 60 million people. Most of the doses will be made in Japan by pharmaceutical firms Daiichi Sankyo Co (4568.T), JCR Pharmaceuticals Co (4552.T) and other local partners.

Japan approves AstraZeneca COVID vaccine ahead of Tokyo Olympics

AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, 4 to 8 June 2021. More than 100 abstracts will feature 21 approved and potential new medicines across the Company’s industry-leading oncology portfolio, with four abstracts selected as late-breakers, 12 oral presentations and one plenary presentation.

In secondary endpoints, Fasenra sustained the reduction in asthma exacerbation rates observed during predecessor Phase 3 trials, with annualized asthma exacerbation rates (AAER) remaining consistently low over the five-year treatment period. AAER decreased from 3.1 exacerbation/year pre-treatment to 0.5 in the predecessor studies with a further reduction to 0.2 by year four of the open-label trial. 59% of patients experienced zero exacerbations during the four years of the open-label period, and at least 75% of patients each year experienced zero exacerbations. In the final year of the trial, 87% of patients experienced zero exacerbations.